Logan examines how pharmaceutical manufacturers must rethink copay assistance in an era affected by maximizers, accumulators, and intensifying payer scrutiny. She argues that brands can both gain a strategic advantage and safeguard adherence by embracing claims-based precision, real-time adaptability, and transparent program design.
Request an analysis of your copay assistance program by emailing Paysign at affordability@paysign.com or by visiting paysign.com/rx.
Read on for Logan’s insights.
Reshaping Patient Affordability: The Power of Expertise and Agility
By Logan Melchione, VP of Patient Affordability, Paysign
Innovation in patient affordability is about effectiveness through due diligence. The patient affordability landscape grows increasingly challenging, with impacts from maximizers and accumulators diverting billions in manufacturer-funded patient support.
Pharmaceutical brands need solutions grounded in deep industry expertise and designed with a true understanding of the issue at hand, as well as the potential impact to the patients and pharmacies. This evolution is reshaping the approach to copay assistance, with forward-thinking pharma brands understanding the need for an intelligent program design. They’re recognizing that empirical methods coupled with transparency consistently outperform the blanket, sometimes careless, approach, and that the most effective solutions adapt to the needs of each brand and their patients and pharmacies.
Solution providers must understand that thriving in this environment requires accepting a fundamental truth: mastery is an ever-changing objective requiring the depth of knowledge, rigorous scrutiny, and the power of partnership to achieve success. From these things comes true innovation.
Solving Over Mitigation: Advanced Accuracy Through Claims-Based Logic
For over a decade, legacy copay providers have been resistant to challenge existing norms, leading to stagnant solutions that offer little savings. Manufacturers are often presented with maximizer solutions that “total up” the dollar spend to a known number, e.g., Affordable Care Act maximum out-of-pocket, and consider a patient “impacted.” By that time, more than 35% of the potential program dollar savings are gone.
Other enrollment-based solutions rely on data collected directly from the patient during sign-up and compare it to aggregated data—but could include information brands don’t want to capture or that patients don’t have handy. Both options fail to address patient, pharmacy, and provider level communication. These are critical issues that may cause therapy abandonment, even before the first fill has happened.
Modern, effective solutions should adapt to the patient, and not the other way around. Each time insurance changes and they move into or out of a maximizer, your solution should adjust. This means utilizing a claims-based solution in real time, at first fill, with extremely high identification accuracy (97%-98%). This level of accuracy, paired with concise messaging, drastically limits any disruption to the patient journey, which should be a fundamental requisite of all maximizer solutions.
Targeted expansion of a service provider’s solution is a critical expectation for manufacturers as well. Since most copay maximizer programs operate differently, your service provider’s solution must be dynamic with the ability to expand following comprehensive investigation and evidence-based testing. This process is paramount for effective solution expansion while maintaining nearly perfect first fill identification and minimal patient disruption. While this approach may seem obvious, the lack of due diligence and precision is a common issue with industry solutions utilizing a blanket approach—leading to increased margins for error and patient abandonment.
Transparency and collaboration are important elements for an effective maximizer solution. Manufacturers should expect the following:
- Daily reporting on the solution’s effectiveness per maximizer program
- Regular status updates on maximizer solution expansion and targeting
- Defined escalation process for misidentified maximizer patients
- In-depth patient adherence analysis
Seamless Program Transitions: Invisible to Patients, Invaluable to Manufacturers
One of the most overcomplicated processes within patient affordability is the program transition experience. When faced with the decision to change service providers, manufacturers must weigh the risk of potential friction and reduced patient adherence. Traditional program transition methodologies rely heavily on patients to ensure they follow new and updated program requirements. We believe this process should be completely behind the scenes involving primarily the service provider and the pharmacy instead. No complicated steps for patients to follow. Just seamless continuation of therapy.
This practical approach recognizes that every point of friction is a potential abandonment point. Seamless program transitions see higher retention, better adherence, and more positive patient impact. Using common-sense methods make this process painless to those who matter most—the patients.
The Bottom Line: Your Partner Is Your Advantage
As I’ve witnessed throughout my career, the patient affordability landscape will continue evolving. Payor tactics will grow more aggressive. Regulatory scrutiny will intensify. Manufacturers partnered with expert service providers—like Paysign—who deliver transparency, real-time adaptation, innovative program design, and seamless execution will capture competitive advantages. Those relying on legacy systems, outdated approaches, or blanket solutions may underperform because they lacked the support of partnership and expertise that could have made a difference.
Paysign believes the new standard in patient affordability isn’t defined by bold claims or fleeting trends—we define it as delivering measurable solutions that strengthen outcomes for manufacturers, and most importantly, support patients. We prioritize effectiveness over unnecessary complexity or blanket approaches, apply deep expertise to a rapidly evolving landscape, and embrace continuous innovation. Paysign provides the level of partnership manufacturers should expect and deserve.
Request an in-depth analysis of your copay assistance program by emailing us at affordability@paysign.com or visit paysign.com/rx.
Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish a guest post on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).
No comments:
Post a Comment